H-Guard® will be evaluated for its safety and efficacy to address serious complement driven complications of haemodialysis GLASGOW, Scotland, Aug. 1, 2023 /PRNewswire/ -- Invizius Limited ("Invizius") ...
RESEARCH TRIANGLE PARK, N.C., March 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company is advancing BCX9930, an oral Factor D inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback